Prognostic impact of P53 status in Ewing sarcoma

Disease stage at the time of diagnosis and response to therapy are the main prognostic factors for patients with Ewing sarcoma or peripheral neuroectodermal tumor (ES/PNET). The primary genetic alteration in ES/PNET, the fusion of the EWS gene with FLI1 or ERG, is diagnostically highly specific for these tumors, and molecular variation in the structure of the EWS‐FLI1 fusion gene also is of prognostic significance. In contrast, secondary genetic alterations, such as P53 alterations, are relatively uncommon in ES/PNET, and their prognostic impact has not been extensively studied.

[1]  G. Wei,et al.  Prognostic impact of INK4A deletion in Ewing sarcoma , 2000, Cancer.

[2]  P. Sorensen,et al.  EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Gerdes,et al.  Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  M. Ladanyi,et al.  Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. , 1999, Cancer research.

[5]  P. Pynsent,et al.  Overexpression of p53 protein in primary Ewing’s sarcoma of bone: relationship to tumour stage, response and prognosis , 1999, British Journal of Cancer.

[6]  A. Huvos,et al.  The Histological Response to Chemotherapy as a Predictor of the Oncological Outcome of Operative Treatment of Ewing Sarcoma* , 1998, The Journal of bone and joint surgery. American volume.

[7]  V. Reuter,et al.  Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation , 1998, Oncogene.

[8]  W. Gerald,et al.  EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  E. Brambilla,et al.  TUNEL Apoptotic Cell Detection in Tissue Sections: Critical Evaluation and Improvement , 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[10]  H. Kovar.  Progress in the Molecular Biology of Ewing Tumors , 1998, Sarcoma.

[11]  S. Fujimoto,et al.  Mutation of the p53 gene in human astrocytic tumours correlates with increased resistance to DNA-damaging agents but not to anti-microtubule anti-cancer agents. , 1998, British Journal of Cancer.

[12]  H. Kovar,et al.  Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors , 1997, Oncogene.

[13]  M. Mansukhani,et al.  The Pattern of P53 and p21WAF1/CIP1 Immunoreactivity in Non‐Hodgkin's Lymphomas Predicts P53 Gene Status , 1997, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[14]  M. Ladanyi,et al.  p53 and MDM2 alterations in osteosarcomas , 1997, Cancer.

[15]  S. Ferrari,et al.  Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[17]  M. Oren,et al.  p53; from inductive signal to cellular effect. , 1997, Current opinion in genetics & development.

[18]  R. Kåresen,et al.  Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas , 1997, The Journal of pathology.

[19]  E. Campo,et al.  p21WAF1/CIP1 AND MDM2 EXPRESSION IN NON‐HODGKIN'S LYMPHOMA AND THEIR RELATIONSHIP TO p53 STATUS: A p53+, MDM2−, p21− IMMUNOPHENOTYPE ASSOCIATED WITH MISSENSE p53 MUTATIONS , 1997, The Journal of pathology.

[20]  H. Choy,et al.  p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma , 1996, Cancer.

[21]  A. Llombart‐Bosch,et al.  Small round blue cell tumors in bone: prognostic factors correlated to Ewing's sarcoma and neuroectodermal tumors. , 1996, Seminars in diagnostic pathology.

[22]  K. Siebenrock,et al.  Comparison of soft tissue Ewing's sarcoma and peripheral neuroectodermal tumor. , 1996, Clinical orthopaedics and related research.

[23]  O. Delattre,et al.  Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Demers,et al.  Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis , 1996, Nature Medicine.

[25]  W. Gerald,et al.  Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  E. Dmitrovsky,et al.  Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. , 1995, Cancer research.

[27]  M. Gebhardt,et al.  p53 overexpression in Ewing's sarcoma/primitive neuroectodermal tumour is an uncommon event , 1995, Clinical molecular pathology.

[28]  W. Gerald,et al.  MDM2 and CDK4 gene amplification in Ewing's sarcoma , 1995, The Journal of pathology.

[29]  T. Triche,et al.  Is neuro-ectodermal differentiation of Ewing's sarcoma of bone associated with an unfavourable prognosis? , 1995, European journal of cancer.

[30]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[31]  T. Triche,et al.  The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. , 1994, The New England journal of medicine.

[32]  D. Givol,et al.  Induction of WAF1/CIP1 by a p53-independent pathway. , 1994, Cancer research.

[33]  G. Thomas,et al.  p53 mutations in human tumors with chimeric EWS/FLI/1 genes , 1994, International journal of cancer.

[34]  C. Cordon-Cardo,et al.  Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. , 1994, Journal of the National Cancer Institute.

[35]  A. Levine,et al.  Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. , 1994, Cancer research.

[36]  P. Sorensen,et al.  A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS–family transcription factor, ERG , 1994, Nature Genetics.

[37]  D. Lane,et al.  p53 In tumour pathology: Can we trust immunohistochemistry?—revisited! , 1994, The Journal of pathology.

[38]  R. Hanada,et al.  Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas. , 1993, Cancer research.

[39]  D. Lane,et al.  What the papers say: The p53‐mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53? , 1993 .

[40]  H. Kovar,et al.  Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. , 1993, Oncogene.

[41]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[42]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[43]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[44]  G. Rosen,et al.  Ewing's sarcoma: Ten‐year experience with adjuvant chemotherapy , 1981, Cancer.